If you’re a medical cannabis patient in the UK and you work in transport, logistics, construction, security, the NHS, social care, or teaching, there’s a good chance you’ve already felt a cold sweat at the mention of a workplace drug test. You’re doing everything right: you have a legal prescription, you’re managing a genuine medical condition, and yet somehow, you’re the one who ends up in a disciplinary meeting. Welcome to one of the most absurd contradictions in UK workplace policy right now.
Releaf, one of the UK’s largest medical cannabis clinics, has flagged that employment issues rank among the top concerns raised by their patients. And honestly, it’s not hard to see why. Patients are testing positive in workplace drug screenings despite having entirely legal prescriptions for cannabis-based medicines. The system simply hasn’t caught up with the reality that cannabis has been legally prescribable in the UK since November 2018, and that makes things deeply unfair for a growing number of workers.
The Prescription Doesn’t Make You Immune From Suspicion
Here’s the thing that most people outside the medical cannabis world don’t realise: there is no standardised workplace drug testing protocol in the UK that differentiates between someone who uses cannabis recreationally on a Friday night and someone who takes a prescribed cannabis-based medicine on the advice of a specialist clinician. The drug test sees THC metabolites, flags a positive result, and that’s often where the nuance ends.
Workers in safety-critical roles, think lorry drivers, scaffolders, security guards, nursing staff, are especially vulnerable. These are sectors where zero-tolerance drug policies exist for good reason. Nobody wants an impaired driver behind the wheel of a 40-tonne lorry. That’s completely fair. But the current blunt-instrument approach doesn’t distinguish between impairment and the presence of a metabolite that can linger for days after a patient takes their prescribed medication. In my view, that’s not safety policy, that’s a liability trap dressed up as duty of care.
Employers, frankly, are often just as lost in all this as their employees. Many HR departments have never had to think about cannabis as a prescribed medicine. Their drug and alcohol policies were written in an era when the answer to any cannabis-positive test was obvious and simple. ACAS guidance on drugs and alcohol at work does acknowledge that employers should consider whether a positive test result is linked to a medical condition, but translating that principle into a working HR policy is a different matter entirely.
Where Trade Unions Come In
This is where Releaf’s insight gets genuinely interesting. The clinic has identified that trade unions are largely unaware that cannabis is legitimately prescribed in the UK at all. Let that sink in for a moment. The very organisations whose entire purpose is to advocate for workers’ rights, to challenge unfair dismissal, to negotiate safe and fair working conditions, many of them simply don’t know that their members might be legally prescribed a cannabis-based medicine.
That’s not a criticism of unions. It’s a reflection of how badly the broader public conversation around medical cannabis has lagged behind the clinical reality. When most people hear “cannabis prescription,” they still picture something controversial or fringe. They don’t picture a pensioner with chronic neuropathic pain who’s been through every other option, or a young woman with endometriosis who finally found something that helps. Understanding how terpene-based cannabis approaches chronic pain management makes it clear this is serious medicine, not a loophole for getting high on the clock.
Honestly, if medical cannabis clinics want to genuinely serve their patients, knocking on union doors isn’t just a nice idea, it’s a clinical responsibility. The consultation doesn’t end when the prescription is written. For patients in safety-critical or zero-tolerance workplaces, the prescription can create as many problems as it solves if there’s no accompanying support structure.
What Would Clinic-Union Collaboration Actually Look Like?
In practice, medical cannabis clinics engaging with trade unions could take several forms:
- Educational briefings: Clinics could deliver training sessions for union reps explaining what medical cannabis is, how it’s prescribed, what conditions it treats, and what patients’ legal rights look like in a workplace context.
- Policy templates: Clinics could work with unions to draft model workplace drug testing policies that account for prescribed cannabis-based medicines alongside other legal prescription medications.
- Case support: When a patient faces disciplinary action, having a union rep who actually understands the clinical picture could make a transformative difference to the outcome.
- Joint advocacy: Together, clinics and unions could lobby employers, industry bodies, and ultimately government for clearer statutory guidance on prescribed cannabis in the workplace.
Let’s be real, this is the kind of joined-up thinking that the medical cannabis sector has historically been bad at. Too often, clinics have focused on the clinical side and left patients to figure out the rest on their own. The patients who are most at risk here aren’t tech workers in liberal offices who can quietly disclose to an understanding manager. They’re workers in physically demanding, heavily unionised industries where drug testing is both routine and consequential.
The Broader Picture: 1.8 Million Patients and Counting
Estimates suggest there are around 1.8 million people in the UK using cannabis for medicinal purposes, though the vast majority are still sourcing it illicitly. The legal prescribed patient population is smaller but growing rapidly. As more patients come through the legitimate clinical pathway, the employment dimension of medical cannabis is only going to grow.
I think what’s needed is a cultural shift in how workplaces treat prescribed medication generally, and cannabis-based medicines specifically. The same employer who would never dream of disciplining an employee for taking prescribed opioids or benzodiazepines, both of which can impair function far more acutely than many cannabis-based preparations, might still instinctively treat a positive cannabis test as grounds for dismissal. That inconsistency is hard to justify on safety grounds alone.
For workers who want to understand more about how terpenes in cannabis contribute to pain relief, the science is increasingly robust. These aren’t experimental fringe treatments. They’re medicines prescribed by qualified clinicians for conditions that aren’t adequately managed by conventional options.
What Patients Can Do Right Now
While the sector figures out its strategy, patients aren’t completely without options. Here’s what I’d suggest thinking about:
- Know your rights: The Equality Act 2010 may offer some protection if your underlying condition qualifies as a disability. This doesn’t make a positive drug test automatically acceptable to your employer, but it does mean they have a duty to make reasonable adjustments.
- Disclose carefully: Disclosure is a deeply personal decision. Some employers will respond well; others won’t. Talking to a union rep or employment solicitor before disclosing is worth doing.
- Document everything: Keep your prescription documentation in order. Carry a letter from your prescribing clinic if you’re in a role with routine testing.
- Join your union: If you’re in a sector with a relevant union and you’re not already a member, now is a good time. Unions exist precisely for moments like this.
It’s also worth noting that the shifting landscape of cannabis legalisation globally is creating pressure for UK policy to evolve further. As more jurisdictions normalise cannabis use, the pressure on UK employers to update outdated drug testing frameworks will only increase.
A Final Word on Getting This Right
Medical cannabis in the UK is no longer niche. It’s a growing clinical practice with a growing patient population, many of whom are also employees, union members, and contributors to industries that depend on their labour. The gap between what is legal and what is operationally understood in workplaces is a real source of harm for real people.
Releaf is right to call this out. And any clinic that genuinely cares about patient outcomes should be picking up the phone to Unite, the GMB, Unison, or whichever union is relevant to their patient population’s sector. Not because it’s good PR, though it would be, but because their patients need them to.
In my view, the medical cannabis sector has spent enough time explaining itself to regulators and sceptical doctors. It’s time to start explaining itself to the people who can actually protect patients in their day-to-day lives: their union reps. For more background on cannabis education and terpenes, and how the broader science supports these medicines, there’s a wealth of information worth exploring before your next appointment, or your next disciplinary hearing.
